GenMont Biotech Inc
TWSE:3164
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (6.7), the stock would be worth NT$25.1 (42% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.7 | NT$17.7 |
0%
|
| 3-Year Average | 6.7 | NT$25.1 |
+42%
|
| 5-Year Average | 6.4 | NT$23.83 |
+35%
|
| Industry Average | 418.5 | NT$1 565.38 |
+8 744%
|
| Country Average | 9.2 | NT$34.5 |
+95%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
|
GenMont Biotech Inc
TWSE:3164
|
1.5B TWD | 4.7 | 26.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 9.6 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 7.2 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 7.6 | 19.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 9.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 4.2 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 6.4 | 29.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 6.4 |
| Median | 9.2 |
| 70th Percentile | 14.1 |
| Max | 10 648.4 |
Other Multiples
GenMont Biotech Inc
Glance View
Genmont Biotech Inc. engages in the research of new functional bacteria as well as the manufacturing and sale of probiotic powder. The company is headquartered in Tainan, Tainan. The company went IPO on 2003-06-12. The firm's major products include lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus fermentum, lactobacillus salivarius, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus brevis, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus johnsonii and others. The Company’s products are applied to enhance human immunity against dust allergy and digestive system health care. The firm distributes its products in domestic market and to overseas markets.
